---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-010177"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2024-01-18T23:59:59+00:00"
generated_at: "2026-06-06T21:58:44.643103+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma cuts workforce 30%, extends cash runway to end of 2026

## Summary
- Workforce reduction of ~30% to prioritize PC14586 development and streamline operations.
- Unaudited cash, cash equivalents, and marketable securities of ~$229M as of Dec 31, 2023.
- Expected non-recurring charges of ~$1.4M for employee severance and benefits, mainly in Q1 2024.
- Cash runway now expected to extend to end of 2026 due to cost savings.
- Registrational Phase 2 trial for PC14586 remains on track to initiate in Q1 2024.

## SEC filing metadata
- accession: 0001193125-24-010177
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2024-01-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000119312524010177/0001193125-24-010177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000119312524010177/d695291d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-010177
- JSON: https://secwatch.observer/filing/0001193125-24-010177.json
- Plain text: https://secwatch.observer/filing/0001193125-24-010177.txt

## Key facts
- Restructurings & Charges
  PMV Pharmaceuticals, Inc. announced a restructuring with charges of approximately $1.4 million (approximately 30% of the Company’s employees).
  - Type: restructuring
  - Charge: approximately $1.4 million
  - Headcount: approximately 30% of the Company’s employees
  source text: development for its lead product candidate, PC14586. As a result of the reduction in force, the Company expects to incur aggregate non-recurring charges of approximately $1.4 million, consisting primarily of employee severance and benefit costs associated with the restructuring. The Company expects that most of these charges will be cash expenditures and that
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000119312524010177/0001193125-24-010177-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.